A Novel Approach to Assessing Infants With Neonatal Abstinence Syndrome
Article Figures & Data
Figures
- FIGURE 1
ESC approach.
- FIGURE 2
FNASS approach.
- FIGURE 3
Disagreements between the ESC and FNASS approaches.
Tables
- TABLE 1
Characteristics of the Infant and Their Mothers
Baseline (N = 50) Characteristics of the Infants Girls, n (%) 28 (56) Race, n (%)a White 45 (92) African American 3 (6) Hispanic 1 (2) Birth weight, kgb 3.1 ± 0.5 Apgar score at 5 minb 8.9 ± 0.3 Head circumference, cmb 32.9 ± 1.6 Breastfed, n (%)c 18 (36) Maximum weight loss from birth weight, %b 8.7 ± 2.6 Weight loss from birth weight at discharge, %b 7.2 ± 3.3 Length of stay, db 5.9 ± 2.1 Characteristics of the mothers Mother’s age, yb 28.4 ± 5.0 Gestational age, wkb 38.8 ± 1.5 Gravidab 3.1 ± 2.2 Cesarean delivery, n (%) 11 (22) Cigarette smoking, n (%) 22 (44) Alcohol, n (%) 3 (6) Public insurance, n (%) 44 (88) Opioid used, n (%) Methadone 40 (80) Buprenorphine 7 (14) Otherd 3 (6) Methadone dose, mg/db 87.8 ± 37.2 Polypharmacy, n (%)e 21 (42) ↵a Data were unavailable for 2 patients.
↵b Mean ± SD.
↵c Breast milk >50% of intake at discharge.
↵d Oxycodone, Oxycontin, and/or Percocet.
↵e Opioid use in addition to mother’s use of cocaine, selective serotonin reuptake inhibitors, or benzodiazepines (determined either via history and/or urine testing of mother).
- TABLE 2
Outcomes
Outcome Using ESC Approach Predicted Outcome Using FNASS Approach P Infants with NAS receiving morphine, n (%) 6 (12) 31 (62) <.001 Hospital days, n (%)a No morphine 258 (87.2) 156 (52.7) <.001 Increased morphine dose 8 (2.7) 76 (25.7) <.001 Decreased morphine dose 21 (7.1) 35 (11.8) <.001 Same morphine dose 9 (3.0) 29 (9.8) <.001 ↵a N = 296.
Data Supplement
